| 发明名称 | Immunoconjugate for human CD66 for the treatment of multiple myeloma and other haematological malignancies | ||
| 摘要 | The present invention relates to the use of radioimmunoconjugates for the treatment of haematological malignancies, particularly multiple myeloma. | ||
| 申请公布号 | US9072797(B2) | 申请公布日期 | 2015.07.07 |
| 申请号 | US200612097508 | 申请日期 | 2006.11.30 |
| 申请人 | THERAPHARM GMBH | 发明人 | Benes Ivan;Bosslet Klaus;Orchard Kim |
| 分类号 | A61K51/10;A61K47/48;C07K16/28 | 主分类号 | A61K51/10 |
| 代理机构 | Kilpatrick Townsend & Stockton LLP | 代理人 | Kilpatrick Townsend & Stockton LLP |
| 主权项 | 1. A method for treating multiple myeloma, the method comprising a therapeutic step of administering a therapeutic radioimmunoconjugate (RIC) to a human subject suffering from multiple myeloma, wherein the therapeutic RIC comprises a CD66-binding component and radionuclide yttrium-90 (90Y), the CD66-binding component being (1) a BW250/183 antibody in the murine, humanized, or recombinant form and (2) covalently linked to the radionuclide via chelating agent isothiocyanato-benzyl-S-methyl -diethylenetriaminepentaacetic acid (ITC-2B3M-DTPA). | ||
| 地址 | Zug CH | ||